Equity Details
Price & Market Data
Price: $1.57
Daily Change: +$0.13 / 8.28%
Daily Range: $1.37 - $1.57
Market Cap: $64,558,120
Daily Volume: 38,607
Performance Metrics
1 Week: 4.90%
1 Month: -11.76%
3 Months: 15.38%
6 Months: -15.73%
1 Year: -10.71%
YTD: -9.64%
About BeyondSpring Inc. (BYSI)
Stay ahead with market insights for BeyondSpring Inc. (BYSI). The stock is currently at 1.57, having moved by +$0.13 / 8.28% today. Its impressive market capitalization is 64,558,120. Find out how it has performed year-to-date and over 1, 3, 6, and 12 months.
Company Details
Employees: 44
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
